Fulranumab Shows Efficacy for Osteoarthritis Pain

On the Brief Pain Inventory-Short Form, patients in the 3–mg every 4 weeks and 10–mg every 8 weeks subgroups had significant average reductions compared with the placebo group for the subscales of pain intensity and pain interference with activities The three highest-dosage subgroups also produced average drops in patient global assessment of disease status that were statistically significant compared with the placebo group's average.

In a separate poster at the meeting, Dr. Thipphawong and his associates also reported that several of the fulranumab subgroups showed statistically significant average improvements compared with placebo in several subscale measures on the Short Form-36, specifically bodily pain, vitality, and physical component. The four highest-dosage subgroups also had significant average improvements in pain interference with sleep compared with placebo, and all five fulranumab dosage subgroups had significant average improvements in sleep adequacy compared with the placebo group.